MUTUAL TERMINATION AND RELEASE AGREEMENTMutual Termination and Release Agreement • November 30th, 2012 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This MUTUAL TERMINATION AND RELEASE AGREEMENT (this “Agreement”), dated as of November 29, 2012, by and between Presidio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“Parent”), S Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“Merger Sub”), 667, L.P., a Delaware limited partnership (“667”), Baker Bros. Investments II, L.P., a Delaware limited partnership (“BB Investments”), Baker Brothers Life Sciences, L.P., a Delaware limited partnership (“BB Life Sciences”), 14159, L.P., a Delaware limited partnership (“14159”), Bay City Capital Fund IV, L.P., a Delaware limited partnership (“Bay City”), Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (“Bay City Co-Investment”), Ventures West 8 Limited Partnership, an Ontario limited partnership (“Ventures West”), New Leaf Ventures II, L.P., a Delaware limited partnership (“New Leaf”), and Panorama Capital, L.P
